Dorthe Viemose Nielsen1, Malene Kærslund Hansen, Søren Paaske Johnsen, Mads Hansen, Karsten Hindsholm, Carl-Johan Jakobsen. 1. From the Department of Anesthesiology and Intensive Care (D.V.N., C.-J.J.) and Department of Clinical Epidemiology (M.K.H., S.P.J.), Aarhus University Hospital, Aarhus, Denmark; Department of Anesthesia and Intensive Care, Odense University Hospital, Odense, Denmark (M.H.); and Department of Anesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark (K.H.).
Abstract
BACKGROUND: Inotropes used to obtain short-term hemodynamic benefits in cardiac surgery may carry a risk of increased myocardial ischemia and adverse outcomes. This study investigated the association between intra- and postoperative use of inotropes and mortality and postoperative complications. METHODS: A historic cohort study using prospective data from the Western Denmark Heart Registry on 6,005 consecutive cardiac surgery cases from three university hospitals. Propensity matching on pre- and intraoperative variables was used to identify a subgroup of patients receiving inotropic therapy (n = 1,170) versus comparable nonreceivers (n = 1,170) for outcome analysis. RESULTS: Two thousand ninety-seven patients (35%) received inotropic therapy; 3,908 (65%) did not receive any inotropic or vasopressor support perioperatively. Among propensity-matched cohort including 2,340 patients 30-day mortality was 3.2% and 1-yr mortality was 7.6%. In the matched cohort, patients exposed to inotropes had a higher 30-day mortality (adjusted hazards ratio, 3.7; 95% CI, 2.1 to 6.5) as well as a higher 1-yr mortality rate (adjusted hazards ratio, 2.5; 95% CI, 1.8 to 3.5) compared with nonreceivers. Among propensity-matched, the following absolute events rates were observed: myocardial infarction 2.4%, stroke 2.8%, arrhythmia 35%, and renal replacement therapy 23.9%. Inotropic therapy was independently associated with postoperative myocardial infarction (adjusted odds ratio, 2.1; 95% CI, 1.4 to 3.0), stroke (adjusted odds ratio, 2.4; 95% CI, 1.4 to 4.3), and renal replacement therapy (adjusted odds ratio, 7.9; 95% CI, 3.8 to 16.4). CONCLUSION: Use of intra- and postoperative inotropes was associated with increased mortality and major postoperative morbidity.
BACKGROUND: Inotropes used to obtain short-term hemodynamic benefits in cardiac surgery may carry a risk of increased myocardial ischemia and adverse outcomes. This study investigated the association between intra- and postoperative use of inotropes and mortality and postoperative complications. METHODS: A historic cohort study using prospective data from the Western Denmark Heart Registry on 6,005 consecutive cardiac surgery cases from three university hospitals. Propensity matching on pre- and intraoperative variables was used to identify a subgroup of patients receiving inotropic therapy (n = 1,170) versus comparable nonreceivers (n = 1,170) for outcome analysis. RESULTS: Two thousand ninety-seven patients (35%) received inotropic therapy; 3,908 (65%) did not receive any inotropic or vasopressor support perioperatively. Among propensity-matched cohort including 2,340 patients 30-day mortality was 3.2% and 1-yr mortality was 7.6%. In the matched cohort, patients exposed to inotropes had a higher 30-day mortality (adjusted hazards ratio, 3.7; 95% CI, 2.1 to 6.5) as well as a higher 1-yr mortality rate (adjusted hazards ratio, 2.5; 95% CI, 1.8 to 3.5) compared with nonreceivers. Among propensity-matched, the following absolute events rates were observed: myocardial infarction 2.4%, stroke 2.8%, arrhythmia 35%, and renal replacement therapy 23.9%. Inotropic therapy was independently associated with postoperative myocardial infarction (adjusted odds ratio, 2.1; 95% CI, 1.4 to 3.0), stroke (adjusted odds ratio, 2.4; 95% CI, 1.4 to 4.3), and renal replacement therapy (adjusted odds ratio, 7.9; 95% CI, 3.8 to 16.4). CONCLUSION: Use of intra- and postoperative inotropes was associated with increased mortality and major postoperative morbidity.
Authors: Maria Tafelmeier; Teresa Weizenegger; Sarah Ripfel; Miriam Fauser; Bernhard Floerchinger; Daniele Camboni; York Zausig; Sigrid Wittmann; Marzena A Drzymalski; Florian Zeman; Christof Schmid; Lars S Maier; Stefan Wagner; Michael Arzt Journal: Clin Res Cardiol Date: 2018-06-12 Impact factor: 5.460
Authors: Majed Afana; Mahmoud Altawil; Mir Basir; Mohammad Alqarqaz; Khaldoon Alaswad; Marvin Eng; William W O'Neill; Robert J Lederman; Adam B Greenbaum Journal: Catheter Cardiovasc Interv Date: 2020-09-09 Impact factor: 2.585
Authors: Jimmy T Efird; William F Griffin; Daniel F Sarpong; Stephen W Davies; Iulia Vann; Nathaniel T Koutlas; Ethan J Anderson; Patricia B Crane; Hope Landrine; Linda Kindell; Zahra J Iqbal; T Bruce Ferguson; W Randolph Chitwood; Alan P Kypson Journal: Int J Environ Res Public Health Date: 2015-07-06 Impact factor: 3.390
Authors: Emily A Vail; Meng-Shiou Shieh; Penelope S Pekow; Hayley B Gershengorn; Allan J Walkey; Peter K Lindenauer; Hannah Wunsch Journal: Ann Am Thorac Soc Date: 2021-01